Drug & intervention
tirzepatide
RxCUI 2601723
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownA Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744 · 2026-09-11
RECRUITINGA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightNCT07842640 · 2026-08-27
RECRUITINGTirzepatide in Idiopathic Intracranial Hypertension TrialNCT07191873 · 2026-08-25
RECRUITINGIncretin Therapies in Obesity-related HFpEFNCT07554638 · 2026-08-07
RECRUITINGTirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsNCT07257484 · 2026-06-08
RECRUITINGA Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood SugarNCT07284511 · 2026-05-19
RECRUITINGTirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · 2026-04-27
RECRUITINGResistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With ObesityNCT07228741 · 2026-04-23
RECRUITINGThe Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · 2026-04-08
RECRUITINGEffects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsNCT06811324 · 2026-04-01
RECRUITINGEfficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesNCT07521631 · 2026-03-31
RECRUITINGCombination of Biologic and Anti-obesity Therapies in Psoriatic ArthritisNCT07443956 · 2026-03-09
RECRUITINGA Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846 · 2026-03-02
RECRUITINGPathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal TumorsNCT07095517 · 2026-02-24
RECRUITINGEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)NCT07481747 · 2026-02-02
RECRUITINGTirzepatide and Muscle Outcomes in ObesityNCT07373834 · 2026-01-01
RECRUITINGA Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young AdultsNCT07364175 · 2026-01-01
RECRUITINGTirzepatide (Spartina) in Obese Kidney Transplant RecipientsNCT07423247 · 2026-01-01
RECRUITINGA Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)NCT07247084 · 2025-11-24
RECRUITINGEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityNCT05933499 · 2025-11-05
RECRUITINGMetabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialNCT07202247 · 2025-11-05
RECRUITINGPhase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and ObesityNCT07245771 · 2025-11-04
RECRUITINGGLP-1R Actions on Muscle and the SkeletonNCT07154719 · 2025-10-09
RECRUITINGTirzepatide for Alcohol Use DisorderNCT06994338 · 2025-10-06
RECRUITINGEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating DisorderNCT06847399 · 2025-09-17
RECRUITINGTirzepatide Use in People With Obesity and Type 1 DiabetesNCT07096908 · 2025-07-31
RECRUITINGPre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyNCT06759701 · 2025-07-02
RECRUITINGEffect of Tirzepatide on Markers of MASLD in Patients With ObesityNCT06934642 · 2025-06-30
RECRUITINGMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · 2025-06-26
RECRUITINGMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · 2025-06-26
RECRUITINGSemaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityNCT07293325 · 2025-06-02
RECRUITINGTirzepatide in PWS, HO and GNSONCT06901245 · 2025-05-01
RECRUITINGTIRzepatide for the Treatment of Obesity in Patients With Atrial FibrillationNCT06802081 · 2025-04-08
RECRUITINGA Study of BGM0504 in Participants With ObesityNCT06911203 · 2025-04-03
RECRUITING2024 Tirzepatide-Bariatric SurgeryNCT06721507 · 2025-03-27
RECRUITINGA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · 2025-03-19
RECRUITINGGlucagon-Like Peptide-1 Receptor Agonist in ADPKDNCT06582875 · 2025-03-06
RECRUITINGGIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 DiabetesNCT06630585 · 2025-02-14
RECRUITINGNormal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideNCT06657209 · 2025-01-13
RECRUITINGA Study of a Weight Loss Intervention in People With Endometrial CancerNCT06751589 · 2024-12-19
RECRUITINGConditions being studied
Obesity81Overweight31Type 2 Diabetes22Diabetes Mellitus, Type 213Obesity & Overweight8Type 2 Diabetes Mellitus8Obesity (Disorder)5Obesity and Overweight4Atrial Fibrillation3Endometrial Cancer3Heart Failure With Preserved Ejection Fraction (HFPEF)3Obesity and Obesity-related Medical Conditions3Overweight and Obesity3Overweight or Obesity3Psoriatic Arthritis3Tirzepatide3Type 1 Diabetes3Weight Loss3Breast Cancer2Cardiovascular (CV) Risk2
Research locations
DallasTexas, United States34HoustonTexas, United States28MiamiFlorida, United States24ChicagoIllinois, United States22Los AngelesCalifornia, United States22San AntonioTexas, United States21New YorkNew York, United States18Buenos AiresArgentina17TopekaKansas, United States17AustinTexas, United States16JacksonvilleFlorida, United States16NorthridgeCalifornia, United States16
Leading sponsors
Eli Lilly and Company64Brigham and Women's Hospital8Novo Nordisk A/S4Shahid Beheshti University of Medical Sciences3Cambridge University Hospitals NHS Foundation Trust2Massachusetts General Hospital2Mayo Clinic2Nanjing First Hospital, Nanjing Medical University2Pennington Biomedical Research Center2Stanford University2The Cleveland Clinic2The University of Texas Health Science Center at San Antonio2UNC Lineberger Comprehensive Cancer Center2University Medical Centre Ljubljana2University of Texas Southwestern Medical Center2
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.